Furthermore, the trial design for ORIENT-11, when initiated in 2018, was consistent with the treatment guidance in China for first-line nonsquamous NSCLC without epidermal growth factor receptor (EGFR) mutations or ALK fusions (39–41). This evidence concerns the gene ALK and non-small cell lung carcinoma.